Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of HL-085 capsules in NRAS-mutant advanced melanoma
CTR20202050Phase 2Completed
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib in melanoma, sponsored by Shanghai KeChow Pharmaceuticals. Started Nov 2020; status: completed.
02
Drugs
tunlametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20202050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202050.